The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Bellerophon Therapeutics COM 078771102 1,823 2,274,370 SH   SOLE   2,274,370 0 0
BioCryst Pharmaceuticals Inc COM 09058V103 24,703 3,061,091 SH   SOLE   3,061,091 0 0
Constellation Pharmaceuticals COM 210373106 267 66,667 SH   SOLE   66,667 0 0
DBV Technologies COM 23306J101 4,088 636,800 SH   SOLE   636,800 0 0
Gemphire Therapeutics COM 36870A108 704 869,538 SH   SOLE   869,538 0 0
Kadmon Holdings Inc. COM 48283N106 4,968 2,388,572 SH   SOLE   2,388,572 0 0
Kalvista Pharmaceuticals COM 483497103 25,377 1,284,931 SH   SOLE   1,284,931 0 0
Kiniksa Pharmaceuticals Ltd COM G5269C101 9,207 327,777 SH   SOLE   327,777 0 0
Marinus Pharmaceuticals Inc COM 56854Q101 3,613 1,258,964 SH   SOLE   1,258,964 0 0
Obseva SA COM H5861P103 14,683 1,159,789 SH   SOLE   1,159,789 0 0
Orchard RX Ltd COM 68570P101 16,383 1,041,515 SH   SOLE   1,041,515 0 0
Protagonist Therapeutics Inc COM 74366E102 2,848 423,176 SH   SOLE   423,176 0 0
Proteostasis Therapeutics Inc COM 74373B109 2,749 848,610 SH   SOLE   848,610 0 0
Ra Pharmaceuticals COM 74933V108 10,824 594,713 SH   SOLE   594,713 0 0
Tricida Inc COM 89610F101 15,341 650,585 SH   SOLE   650,585 0 0